Since therapeutic targeting of the TGF-β/SMAD signalling pathway are being pursued , revealing the identity of factors that modulate the relative activation of Smad2 or Smad3 may provide target(s) for more effective strategies for cancer therapy. The gene discussed is SMAD3; the disease is cancer.